Research programme: HBV cccDNA epigenetic modifiers - Arbutus BiopharmaAlternative Names: cccDNA epigenetic modifiers - Arbutus Biopharma; Covalently closed circular DNA epigenetic modifiers - Arbutus Biopharma
Latest Information Update: 06 Sep 2016
At a glance
- Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
- Developer Arbutus Biopharma; Baruch S. Blumberg Institute
- Class Antivirals; Small molecules
- Mechanism of Action Genetic transcription modulators; Hepatitis B virus replication inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Hepatitis B